In the October issue of The CRISPR Journal, Asymmetrex suggests a “stemgene” solution for the alarming high rate of p53 gene mutations encountered with CRISPR-Cas9 editing of non-transformed cells. Read More
Read the latest news from the MassBio community! This space is for members to share company updates and press releases. Members may not post stories that are copyrighted by news publications or post sales pitches.
Charles River Laboratories announced expansion of its CRISPR/Cas9 service with the addition of a license from ERS Genomics Ltd which allows the offering of custom in vivo and in vitro genome editing. Read More
Charles River Laboratories International, Inc. today launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology. Read More